Erratum: Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies (The Lancet (2010) 375(9726) (1634–1639) (S0140673610605454) (10.1016/S0140-6736(10)60545-4));Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies

The Lancet

Volumn 375, Issue 9726, 2010, Pages 1634-1639

  Sarwar, N ^h   Sandhu, M S ^h   Ricketts, S L ^h   Butterworth, Adam S ^a   Di Angelantonio, Emanuele ^a,h   Matthijs Boekholdt, S ^b   Ouwehand, W ^h   Watkins, H ^h   Samani, N J ^h   Saleheen, D ^h   Lawlor, Debbie ^e   Reilly, Muredach P ^f,h   Hingorani, A D ^h   Talmud, P J ^h   Danesh, J ^h   Braund, P S ^h   Hall, A S ^h   Thompson, J ^h   Marz, W ^h   Trip, M ^h   Lawlor, D A ^h   Casas, J P ^h   Ebrahim, S ^h   Arsenault, B J ^h   Boekholdt, S M ^h   Khaw, K T ^h,h   Wareham, N J ^h   Grallert, H ^h   Illig, T ^h   Humphries, S E ^h   Rader, D J ^h   Clarke, R ^h   Hamsten, A ^h   Hopewell, J C ^h   Frossard, P ^h   Deloukas, P ^h   Ye, S ^h   Simpson, I A ^h   Onat, A ^h   Komurcu Bayrak, E ^h   Martinelli, N ^h   Olivieri, O ^h   Girelli, D ^h   Kivimaki, M ^h   Kumari, M ^h   Aouizerat, B E ^h   Baum, L ^h   Campos, H ^h   Chaaba, R ^h   Chen, B S ^h   Cho, E Y ^h   Evans, D ^h   Hill, J ^h   Hsu, L A ^h   Hubacek, J A ^h   Lai, C Q ^h   Lee, J H ^h   Klos, K ^h   Liu, H ^h   Masana, L ^h   Melegh, B ^h   Nabika, T ^h   Ribalta, J ^h   Ruiz Narvaez, E ^h   Thomas, G N ^h   Tomlinson, B ^h   Szalai, C ^h   Vaverkova, H ^h   Yamada, Y ^h   Yang, Y ^h   Tipping, R W ^h   Ford, C E ^h   Pressel, S L ^h   Ballantyne, C ^h   Brautbar, A ^h   Knuiman, M ^h   Whincup, P H ^h   Wannamethee, S G ^h   Morris, R W ^h   Kiechl, S ^h   Willeit, J ^h   Santer, P ^h   Mayr, A ^h   Wald, N ^h   Yarnell, J W G ^h   Gallacher, J ^h   Casiglia, E ^h   Tikhonoff, V ^h   Cushman, M ^h   Psaty, B M ^h   Tracy, R P ^h   Tybjarg Hansen, A ^h   Nordestgaard, B G ^h   Benn, M ^h   Frikke Schmidt, R ^h   Giampaoli, S ^h   Palmieri, L ^h   Panico, S ^h   Vanuzzo, D ^h   Pilotto, L ^h   Gomez De La Camara A ^h   Gomez Gerique J A ^h   Simons, L ^h   McCallum, J ^h   Friedlander, Y ^h   Fowkes, F G R ^h   Lee, A J ^h   Taylor, J ^h   Guralnik, J M ^h   Phillips, C L ^h   Wallace, R ^h   Blazer, D G ^h   Brenner, H ^h   Raum, E ^h   Muller, H ^h   Rothenbacher, D ^h   Jansson, J H ^h   Wennberg, P ^h   Nissinen, A ^h   Donfrancesco, C ^h   Salomaa, V ^h   Harald, K ^h   Jousilahti, P ^h   Vartiainen, E ^h   D'Agostino R B ^h   Vasan, R S ^h   Pencina, M J ^h   Bladbjerg, E M ^h   Jorgensen, T ^h   Moller, L ^h   Jespersen, J ^h   Dankner, R ^h   Chetrit, A ^h   Lubin, F ^h   Bjorkelund, C ^h   Lissner, L ^h   Bengtsson, C ^h   Cremer, P ^h   Nagel, D ^h   Rodriguez, B ^h   Dekker, J M ^h   Nijpels, G ^h   Stehouwer, C D A ^h   Sato, S ^h   Iso, H ^h   Kitamura, A ^h   Noda, H ^h   Salonen, J T ^h   Nyyssonen, K ^h   Tuomainen, T P ^h   Voutilainen, S ^h   Meade, T W ^h   Cooper, J A ^h   Kuller, L H ^h   Grandits, G ^h   Gillum, R ^h   Mussolino, M ^h   Rimm, E ^h   Hankinson, S ^h   Manson, J A E ^h   Pai, J K ^h   Bauer, K A ^h   Naito, Y ^h   Amouyel, P ^h   Arveiler, D ^h   Evans, A ^h   Ferrieres, J ^h   Schulte, H ^h   Assmann, G ^h   Packard, C J ^h   Sattar, N ^h   Westendorp, R G ^h   Buckley, B M ^h   Cantin, B ^h   Lamarche, B ^h   Despres, J P ^h   Dagenais, G R ^h   Barrett Connor, E ^h   Wingard, D L ^h   Bettencourt, R ^h   Gudnason, V ^h   Aspelund, T ^h   Sigurdsson, G ^h   Thorsson, B ^h   Trevisan, M ^h   Tunstall Pedoe, H ^h   Tavendale, R ^h   Lowe, G D O ^h   Woodward, M ^h   Howard, V ^h   Zhang, Y ^h   Best, L ^h   Umans, J ^h   Ben Shlomo, Y ^h   Davey Smith, G ^h   Njolstad, I ^h   Mathiesen, E B ^h   Lochen, M L ^h   Wilsgaard, T ^h   Ingelsson, E ^h   Lind, L ^h   Giedraitis, V ^h   Michaelsson, K ^h   Brunner, E ^h   Shipley, M ^h   Ridker, P ^h   Buring, J ^h   Shepherd, J ^h   Cobbe, S M ^h   Ford, I ^h   Robertson, M ^h   Marin Ibanez, A ^h   Feskens, E J M ^h   Kromhout, D ^h   Walker, M ^h   Watson, S ^h   Collins, R ^h   Kaptoge, S ^h   Perry, P L ^h   Thompson, A ^h   Thompson, S G ^h   White, I R ^h   Wood, A M ^h   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77951875017     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61076-8     Document Type: Erratum

References (36)

1. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 western prospective studies. Circulation 2007; 115: 450–58
2. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins and risk of vascular disease: individual data analysis of 302,430 participants from 68 prospective studies. JAMA 2009; 302: 1993–2000
3. Phillips A, Davey Smith G. How independent are “independent” eff ects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991; 44: 1223–31
4. Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol 2009; 70: 815–28
5. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 1–22
6. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol,high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008; 40: 189–97
7. Wong K, Ryan RO. Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation. Curr Opin Lipidol 2007; 18: 319–24
8. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008; 299: 2777–88
9. Keating BJ, Tischfi eld S, Murray SS, et al. Concept, design and implementation of a cardiovascular gene-centric 50 K SNP array for large-scale genomic association studies. PLoS One 2008; 3: e3583
10. El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007; 49: 547–53
11. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583–612
12. Fibrinogen Studies Collaboration. Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. Stat Med 2009; 28: 1067–92
13. The Emerging Risk Factors Collaboration. Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. Int J Epidemiol (in press)
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60
15. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371: 1927–35
16. Barter P, Ginsberg HN. Eff ectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol 2008; 102: 1040–45
17. Matsuda D, Tomoda H. DGAT inhibitors for obesity. Curr Opin Investig Drugs 2007; 8: 836–41
18. Hussain MM, Bakillah A. New approaches to target microsomal triglyceride transfer protein. Curr Opin Lipidol 2008; 19: 572–78
19. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362: 906–16
20. Hegele RA, Pollex RL. Apolipoprotein A-V genetic variation and plasma lipoprotein response to fi brates. Arterioscler Thromb Vasc Biol 2007; 27: 1224–27
21. Cardona F, Guardiola M, Queipo-Ortuno MI, et al. The -1131T>C SNP of the APOA5 gene modulates response to fenofi brate treatment in patients with the metabolic syndrome: a postprandial study. Atherosclerosis 2009; 206: 148–52
22. Hubacek JA, Adamkova V, Prusikova M, et al. Impact of apolipoprotein A5 variants on statin treatment effi cacy. Pharmacogenomics 2009; 10: 945–50
23. Gaddi A, Cicero AF, Odoo FO, et al. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag 2007; 3: 877–86
24. Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab 2007; 92: 1581–89
25. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med 2007; 357: 1009–17
26. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106: 2137–42
27. Sarwar N, Sattar N. Triglycerides and coronary heart disease: have recent insights yielded conclusive answers? Curr Opin Lipidol 2009; 20: 275–81
28. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003; 31: 1066–69
29. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007; 18: 427–34
30. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299–308
31. Palmen J, Smith AJ, Dorfmeister B, et al. The functional interaction on in vitro gene expression of APOA5 SNPs, defi ning haplotype APOA52, and their paradoxical association with plasma triglyceride but not plasma apoAV levels. Biochim Biophys Acta 2008; 1782: 447–52
32. Merkel M, Loeffl er B, Kluger M, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005; 280: 21553–60
33. Dichlberger A, Cogburn LA, Nimpf J, et al. Avian apolipoprotein A-V binds to LDL receptor gene family members. J Lipid Res 2007; 48: 1451–56
34. Nilsson SK, Christensen S, Raarup MK, et al. Endocytosis of apolipoprotein AV by members of the low density lipoprotein receptor and the Vps10p domain receptor families. Biol Chem 2008; 283: 25920–27
35. Davey Smith G, Timpson N, Ebrahim S. Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization. Ann Med 2008; 12: 524–41
36. Joy TR, Hegele RA. Microsomal triglyceride transfer protein inhibition-friend or foe? Nat Clin Pract Cardiovasc Med 2008; 5: 506–08.